Policy

Unpacking vaccine pricing: navigating policy, economics, and public health imperatives.

New study finds uneven progress in making data exchange easier and more useful

Rep. Greg Murphy, MD, discusses prior authorizations and other pending legislation in Washington.

Abortion and AI also in the mix at the national level.

Critics air concerns at White House roundtable as pharmacy benefit manager volley back.

More than half of the nation’s state top lawyers pen letter to leaders in House and Senate.

Change takes effect in 2025 and could benefit more than one million Medicare beneficiaries

A new advocacy organization for independent physicians.

A new advocacy organization for independent physicians.

A new advocacy organization for independent physicians.

A new advocacy organization for independent physicians.

A new advocacy organization for independent physicians.

PhRMA, U.S. Chamber warn of unintended consequences, market effects of negotiations.

Administration, HHS tout milestone day on road to lowering drug prices for beneficiaries.

A new advocacy organization for independent physicians.

A new advocacy organization for independent physicians.

A new advocacy organization for independent physicians.

A new advocacy organization for independent physicians.

A new advocacy organization for independent physicians.

It's time for pharmaceutical companies and others to innovate and disrupt the distribution side of treatment.

AIMPA intends to become a new voice for physicians in independent practice.

Prescription drug prices, vaccine costs are also key issues.

In 2024, beneficiaries could see savings per dose, according to new guidance on price increases relative to inflation.

Independent doctors group says cuts would result in higher costs and less access to care for patients

Public-private partnerships will crumble, hurting drug innovation and eventually patients, Republicans say.